Abstract
Background: Following lung transplantation (LT), long-term survival is hindered by the high rate of obliterative bronchiolitis (OB). One major risk factor for the development of OB is recurrent acute rejection (AR). No immunomodulatory regimen has been shown to be more effective than another halting the progression of OB. We report our experience with sirolimus (SIR) in LT pts with OB or recurrent AR.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
